Pfizer has begun testing an omicron vaccine

Pfizer Company / Photo: Archive

The companies "Pfizer "and" Biontek " began a clinical trial of the coronavirus strain omicron vaccine.

The study will assess the safety, tolerability and level of the immune response, and more than 1.400 people are involved in the study.

- Although existing research and data show that booster doses of the vaccine continue to provide a high level of protection against severe disease and hospitalization, we have recognized the need for a new vaccine in case this protection weakens over time and potentially helps "Solving problems caused by omicron or possible new strains in the future," said a statement from Pfizer, a senior vice president and head of vaccine research and development.

The vaccine specifically made against the omicron strain will be given in a dose of 30 micrograms, just like the current vaccine.

Video of the day